#100000
I'm doing an internship <a href=" http://ziplinegear.biz/proofreading-services-review/ ">content writers</a> Until the high court struck down some of Myriad's BRCA patents in June, the company held a monopoly over the tests, though it has said that its remaining patents should continue to bar competitors. BRCA screenings, along with a recommended supplemental test, represented $519.41 million in sales for Myriad in its most recent fiscal year, or 85% of the company's total revenue.
Submitted by Anonymous (not verified) on Wed, 10/29/2014 - 01:06 to Relationships |
